Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cellular therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    346 result(s) found for: Cellular therapy. Displaying page 1 of 18.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-002014-14 Sponsor Protocol Number: COV-PBO-MO28 Start Date*: 2021-04-20
    Sponsor Name:Fakultní nemocnice Hradec Králové
    Full Title: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Medical condition: Antibody and cellular response 28 days after the first dose of COVID-19 vaccine (Moderna) and then 33 weeks after the second dose and 8-12 weeks after the third dose in clinically stable patients w...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005503-17 Sponsor Protocol Number: 200710602 Start Date*: 2011-03-31
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Randomized multicenter double-blind study of phase III in patients after kidney transplantation with an acute cellular rejection with a tubulointerstinal component in kidney transplant with histolo...
    Medical condition: It should be proved that additional treatment with Rituximab in patients with histologic proof of an acute cellular rejection with CD20+ lymphocytes is superior to a solitary therapy with Steroidbo...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001453-74 Sponsor Protocol Number: Version01.1. Start Date*: 2012-05-15
    Sponsor Name:Institute of Specific Prophylaxis and Tropical Medicine
    Full Title: Comparison of vaccination routes: subcutaneus versus intramuscular application of FSME-Immun®
    Medical condition: TBE vaccine (FSME-Immun®) is registered for intra-muscular application. Due to medical reasons (e.g. anticoagulant therapy, adipositas) intra-muscular application is not always possible. The aim o...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004406-42 Sponsor Protocol Number: FCO-TIM-2015-01 Start Date*: 2016-03-10
    Sponsor Name:FIBICO
    Full Title: CLINICAL TRIAL TO ASSEES THE NON-INFERIORITY OF THE SUSPENSION OF PROPHYLACTIC TREATMENT WITH VALGANCICLOVIR IN KIDNEY TRANSPLANT CMV-seropositive PATIENTS, WHO MANTEIN CD8+ CMV- CELLULAR IMMUNI...
    Medical condition: Kidney transplant cytomegalovirus-seropositive
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004385-94 Sponsor Protocol Number: CCTL019E2202 Start Date*: 2018-07-30
    Sponsor Name:Novartis Pharma AG
    Full Title: A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma
    Medical condition: Adult patients with refractory or relapsed follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.0 10016903 - Follicle centre lymphomas, follicular grade I, II, III 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061170 Follicle centre lymphoma, follicular grade I, II, III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) GB (GB - no longer in EU/EEA) AT (Completed) ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002116-14 Sponsor Protocol Number: CCTL019G2201J Start Date*: 2018-10-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive...
    Medical condition: Pediatric and young adult patients aged 1 to 25 years with first-line NCI high-risk (HR) B-cell acute lymphoblastic leukemia (B-ALL) who are in CR1 with minimal residual disease (MRD) positive (MR...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    21.0 100000004864 10063621 Acute lymphoblastic leukaemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) DK (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) NL (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005450-30 Sponsor Protocol Number: ABI-MS-P01 Start Date*: 2014-01-08
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment
    Medical condition: Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000765-12 Sponsor Protocol Number: MICORYX Start Date*: 2011-08-22
    Sponsor Name:Oryx GmbH & Co. KG
    Full Title: Phase I/IIa study of immunization with frameshift peptides administered with Montanide ISA-51 VG in patients with advanced MSI-H colorectal cancer
    Medical condition: advanced MSI-H colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001172-41 Sponsor Protocol Number: ITI-007-503 Start Date*: 2022-01-13
    Sponsor Name:Intra-Cellular Therapies, Inc.
    Full Title: An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025458 Major depressive disorder, recurrent episode, moderate degree LLT
    21.1 100000004873 10081270 Major depressive disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed) BG (Completed) PL (Completed) SE (Completed) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000291-11 Sponsor Protocol Number: IMRES Start Date*: 2021-05-30
    Sponsor Name:Medical University of Vienna
    Full Title: Characterization of immune responsiveness after SARS-CoV-2 Vaccination in patients with Immunodeficiency or immunosuppressive therapy (COVID-19)
    Medical condition: Vaccination against SARS-CoV-2 in immunocompromised patients
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004865 10084462 SARS-CoV-2 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003809-26 Sponsor Protocol Number: SP010 Start Date*: 2013-12-04
    Sponsor Name:SOTIO a.s.
    Full Title: Open-label, one-arm, multi-centre phase II clinical trial with second cycle of active cellular immunotherapy DCVAC/PCa in patients with localized prostate cancer after primary radical prostatectomy...
    Medical condition: Localized prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2022-003303-14 Sponsor Protocol Number: DETACT Start Date*: 2023-02-16
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of Dupilumab on mucus plugs and inflammatory patterns in sEvere asThmatiC paTients (DETACT)
    Medical condition: Severe asthma is a chronic inflammatory condition of the airways, characterized with wheezing, breathlessness, chest tightness and coughing. T2-high asthma is promoted by differentiated T helper c...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000753-22 Sponsor Protocol Number: TV2/003/06 Start Date*: 2006-05-04
    Sponsor Name:Oxford MioMedica UK Ltd.
    Full Title: A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.
    Medical condition: Advanced or Metastatic Renal Cell Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000228-33 Sponsor Protocol Number: CE/17-12-06 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU Saint-Pierre
    Full Title: Prospective longitudinal study on immunogenicity, induction of cellular immune responses and safety of vaccination against HPV with the 9valent vaccine in HIV-positive women
    Medical condition: Immune responses to administration of 9valent vaccine against HPV in HIV-positive women
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10020180 HIV positive LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-005019-15 Sponsor Protocol Number: CCTL019C2202 Start Date*: 2018-11-08
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (N...
    Medical condition: pediatric and adolescents patients with CD19positive r/r mature B-cell NHL who have relapsed after one or more prior therapies or are primary refractory.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) DE (Completed) SE (Ongoing) DK (Completed) NO (Completed) AT (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023230-22 Sponsor Protocol Number: 2010/VCC/0049 Start Date*: 2011-04-12
    Sponsor Name:Velindre NHS Trust
    Full Title: A phase II trial to assess the safety, immunological activity of Trovax plus Pemetrexed/ Cisplatin in patients with malignant pleural mesothelioma.
    Medical condition: The study is for patients with malignant mesothelioma of the lung lining(called pleura).
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035603 Pleural mesothelioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002097-13 Sponsor Protocol Number: SI-05-RG-45 Start Date*: 2017-05-15
    Sponsor Name:Department of Cardiology, University Medical Centre Ljubljana
    Full Title: Comparison of modified-release and standard tacrolimus immunosuppression regimens in heart transplant recipients
    Medical condition: Tacrolimus is a potent immunosuppressant agent widely used for the prevention and treatment of rejection in heart transplant recipients. While tacrolimus is typically administered in two divided do...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003201-14 Sponsor Protocol Number: ERTUSO Start Date*: 2012-03-02
    Sponsor Name: Krankenhaus Nordwest GmbH
    Full Title: Phase I/II, Open Label, Dose Escalating Study To Investigate Safety, Tolerability, And Preliminary Efficacy Of The Trifunctional Anti-HER-2/neu x Anti-CD3 Antibody Ertumaxomab In Patients With HER-...
    Medical condition: Patients with HER2/neu (1+/SISH positive, 2+ and 3+) expressing solid tumors that are progressing after standard therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002766-20 Sponsor Protocol Number: CAUY922A2101 Start Date*: 2009-02-25
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in...
    Medical condition: Dose-expansion study to assess safety, tolerability & efficacy: -One arm (MTD expansion) will enroll advanced cancer patients (other than breast carcinoma). -Two arms (phase II) to assess response ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001040-10 Sponsor Protocol Number: CoVVac Start Date*: 2021-04-26
    Sponsor Name:Medical University of Graz
    Full Title: Humoral and cellular immune response to COVID-19 vaccines in immunocompromised and healthy individuals – The CoVVac study
    Medical condition: Active immunisation to prevent COVID-19 in immunocompromised individuals.
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084457 COVID-19 immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:14:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA